Glucocorticoid
Biologics, glucocorticoids present 'real problem' for managing infection risk
While glucocorticoids are a “real problem” in causing infections among patients with rheumatic and autoimmune diseases, complications linked to biologics should be on the radar for rheumatologists as well, according to a speaker here.
ACR RA guidelines ‘push the needle away’ from glucocorticoids as primary option
Glucocorticoids should no longer be the “default” option for many patients with rheumatoid arthritis, according to authors of a new recommendation document presented at ACR Convergence 2020.
Avacopan reduces glucocorticoid use, recovers renal function in ANCA-associated vasculitis
Treatment with avacopan can reduce glucocorticoid use, improve disease control, and recover renal function among patients with ANCA-associated vasculitis, according to a speaker at ACR Convergence.
Difficult-to-treat RA calls for reassessments of medication, diagnosis
Physicians should confront difficult-to-treat rheumatoid arthritis by rethinking the diagnosis, reassessing available medications, and — importantly — talking with the patient, according to a speaker at the 2020 Congress of Clinical Rheumatology-West.
Glucocorticoids boost infection risk among patients with RA receiving DMARDs
Glucocorticoids are associated with a dose-dependent increase in the risk for serious infections among patients with rheumatoid arthritis receiving DMARDs, according to data published in the Annals of Internal Medicine.
No increased COVID-19 risk with adequately treated adrenal insufficiency
Adults with adrenal insufficiency who are adequately treated and trained display the same incidence of COVID-19-suggestive symptoms and disease severity as controls, according to a presenter.
Tapering canakinumab feasible in patients with juvenile arthritis who achieve remission
Tapering canakinumab in patients with systemic juvenile idiopathic arthritis who achieve remission may be feasible but holding this response may require consistent IL-1 inhibition, according to data published in Arthritis & Rheumatology.
Glucocorticoid use in RA differs greatly, driven by provider preference
Glucocorticoid treatment for rheumatoid arthritis varies greatly among rheumatologists, with provider preference being the greatest predictor of its long-term use, according to data published in Arthritis Care & Research.
Canakinumab improves systemic juvenile idiopathic arthritis regardless of fever
Treatment with canakinumab resulted in rapid, sustained improvements in active systemic juvenile idiopathic arthritis, regardless of whether the patient had a fever at initiation, according to data published in Arthritis & Rheumatology.
Steroid treatment benefits some, may harm others with COVID-19
A blood test to assess C-reactive protein levels in patients with COVID-19 may help determine who would benefit from treatment with glucocorticoid and who would not, according to a study published in the Journal of Hospital Medicine.